New Blood-Saving tactics aim to cut transfusions in kidney cancer surgery

NCT ID NCT04922307

Ongoing Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests special blood-sparing techniques during surgery for advanced kidney cancer. The goal is to reduce the number of donor blood transfusions patients need. About 240 adults with large kidney tumors will be randomly assigned to receive either the blood-sparing protocol or standard care. Researchers will also track complications and long-term outcomes like cancer recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood-sparing techniques (acute normovolemic hemodilution, cell saver, veno-venous bypass)
What this could lead to: If successful, this approach could reduce complications and improve recovery for patients undergoing surgery for advanced kidney cancer.
What could go wrong: This is a relatively small, single-center study, and the techniques may not significantly reduce transfusions or improve outcomes in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER

Contacts and locations

Locations

H. Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States
Winship Cancer Institute at Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.